World Journal of *Gastrointestinal Oncology*

World J Gastrointest Oncol 2023 November 15; 15(11): 1835-2048





Published by Baishideng Publishing Group Inc

WÛ

Governation of Gastrointestinal

Contents

Monthly Volume 15 Number 11 November 15, 2023

REVIEW

1835 Research progress of ginger in the treatment of gastrointestinal tumors Chen GO, Nan Y, Huang SC, Ning N, Du YH, Lu DD, Yang YT, Meng FD, Yuan L

MINIREVIEWS

1852 Glutamine addiction and therapeutic strategies in pancreatic cancer

Ren LL, Mao T, Meng P, Zhang L, Wei HY, Tian ZB

ORIGINAL ARTICLE

Case Control Study

1864 Features of synchronous and metachronous dual primary gastric and colorectal cancer Lin YJ, Chen HX, Zhang FX, Hu XS, Huang HJ, Lu JH, Cheng YZ, Peng JS, Lian L

Retrospective Study

- 1874 Conditional survival probability of distant-metastatic hepatocellular carcinoma: A population-based study Yang YP, Guo CJ, Gu ZX, Hua JJ, Zhang JX, Shi J
- 1891 MUTYH-associated polyposis: Is it time to change upper gastrointestinal surveillance? A single-center case series and a literature overview

Sanchez-Mete L, Mosciatti L, Casadio M, Vittori L, Martayan A, Stigliano V

1900 Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma

Dharmapuri S, Özbek U, Jethra H, Jun T, Marron TU, Saeed A, Huang YH, Muzaffar M, Pinter M, Balcar L, Fulgenzi C, Amara S, Weinmann A, Personeni N, Scheiner B, Pressiani T, Navaid M, Bengsch B, Paul S, Khan U, Bettinger D, Nishida N, Mohamed YI, Vogel A, Gampa A, Korolewicz J, Cammarota A, Kaseb A, Galle PR, Pillai A, Wang YH, Cortellini A, Kudo M, D'Alessio A, Rimassa L, Pinato DJ, Ang C

Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with 1913 metastatic colorectal cancer

Mullin G, Sternschuss M, Landman Y, Sulkes A, Brenner B

1925 Application of sintilimab combined with anlotinib hydrochloride in the clinical treatment of microsatellite stable colorectal cancer

Feng R, Cheng DX, Chen XC, Yang L, Wu H

Basic Study

1936 Dopamine and cyclic adenosine monophosphate-regulated phosphoprotein with an apparent Mr of 32000 promotes colorectal cancer growth

He K, Xie CZ, Li Y, Chen ZZ, Xu SH, Huang SQ, Yang JG, Wei ZQ, Peng XD



Conter	World Journal of Gastrointestinal Oncology Monthly Volume 15 Number 11 November 15, 2023
1951	Identification of necroptosis-related lncRNAs for prognosis prediction and screening of potential drugs in patients with colorectal cancer
	Chen ZH, Lin YL, Chen SQ, Yang XY
1974	Long non-coding RNA CDKN2B-AS1 promotes hepatocellular carcinoma progression <i>via</i> E2F transcription factor 1/G protein subunit alpha Z axis
	Tao ZG, Yuan YX, Wang GW
	META-ANALYSIS
1988	Efficacy and safety of gastroscopic hemostasis in the treatment of acute gastric hemorrhage: A meta- analysis
	Pan HY, Wang XW, He QX, Lu YD, Zhang WY, Jin JW, Lin B
1998	Application of convolutional neural network-based endoscopic imaging in esophageal cancer or high- grade dysplasia: A systematic review and meta-analysis
	Zhang JQ, Mi JJ, Wang R
2017	Role of routine lymph node dissection alongside resection of intrahepatic cholangiocarcinoma: Systematic review and meta-analysis
	Atif M, Borakati A, Mavroeidis VK
	CASE REPORT
2033	Response of cholangiocarcinoma with epigastric metastasis to lenvatinib plus sintilimab: A case report and review of literature
	Luo WH, Li SJ, Wang XF

2041 Pancreatic pseudoaneurysm mimicking pancreatic tumor: A case report and review of literature Yang Y, Liu XM, Li HP, Xie R, Tuo BG, Wu HC



Contents

Monthly Volume 15 Number 11 November 15, 2023

ABOUT COVER

Editorial Board Member of World Journal of Gastrointestinal Oncology, Le-Le Song, MD, PhD, Associate Professor, Doctor, Department of Radiotherapy, The Eighth Medical Center of the Chinese PLA General Hospital, Beijing 100091, China. songlele@sina.com

AIMS AND SCOPE

The primary aim of World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING

The WJGO is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJGO as 3.0; IF without journal self cites: 2.9; 5-year IF: 3.0; Journal Citation Indicator: 0.49; Ranking: 157 among 241 journals in oncology; Quartile category: Q3; Ranking: 58 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2022 is 4.1 and Scopus CiteScore rank 2022: Gastroenterology is 71/149; Oncology is 197/366.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Xiang-Di Zhang; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL World Journal of Gastrointestinal Oncology	INSTRUCTIONS TO AUTHORS https://www.wjgnet.com/bpg/gerinfo/204
ISSN	GUIDELINES FOR ETHICS DOCUMENTS
ISSN 1948-5204 (online)	https://www.wjgnet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
February 15, 2009	https://www.wjgnet.com/bpg/gerinfo/240
FREQUENCY	PUBLICATION ETHICS
Monthly	https://www.wjgnet.com/bpg/GerInfo/288
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT
Monjur Ahmed, Florin Burada	https://www.wjgnet.com/bpg/gerinfo/208
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/1948-5204/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS
November 15, 2023	https://www.wjgnet.com/bpg/GerInfo/239
COPYRIGHT	ONLINE SUBMISSION
© 2023 Baishideng Publishing Group Inc	https://www.f6publishing.com

© 2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com



0 WÛ

World Journal of **Gastrointestinal** Oncology

Submit a Manuscript: https://www.f6publishing.com

World J Gastrointest Oncol 2023 November 15; 15(11): 1988-1997

DOI: 10.4251/wjgo.v15.i11.1988

ISSN 1948-5204 (online)

META-ANALYSIS

Efficacy and safety of gastroscopic hemostasis in the treatment of acute gastric hemorrhage: A meta-analysis

Hai-Yan Pan, Xiao-Wei Wang, Qiong-Xiao He, Yi-Dan Lu, Wan-Yi Zhang, Jian-Wei Jin, Bin Lin

Specialty type: Oncology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): B Grade C (Good): C Grade D (Fair): 0 Grade E (Poor): 0

P-Reviewer: Billeter A, Germany; Choi S, South Korea

Received: August 24, 2023 Peer-review started: August 24, 2023

First decision: September 11, 2023 Revised: September 19, 2023 Accepted: September 27, 2023 Article in press: September 27, 2023 Published online: November 15, 2023



Hai-Yan Pan, Qiong-Xiao He, Wan-Yi Zhang, Bin Lin, Department of Emergency Medicine, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310005, Zhejiang Province, China

Xiao-Wei Wang, Department of Cardiopulmonary Rehabilitation, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310005, Zhejiang Province, China

Yi-Dan Lu, Department of Ultrasound, Zhejiang Cancer Hospital, Hangzhou 310005, Zhejiang Province, China

Jian-Wei Jin, Department of Oncology, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310005, Zhejiang Province, China

Corresponding author: Bin Lin, MS, Staff Physician, Department of Emergency Medicine, The Third Affiliated Hospital of Zhejiang Chinese Medical University, No. 219 Moganshan Road, Hangzhou 310005, Zhejiang Province, China. 18268051213@163.com

Abstract

BACKGROUND

Gastric cancer (GC) is a malignant tumor with a high incidence and mortality rate worldwide for which acute bleeding is a common clinical complication. Gastroscopic hemostasis is an important method for treating acute bleeding in GC; however, its efficacy and safety remain controversial.

AIM

To systematically analyze the efficacy and safety of gastroscopic hemostasis for the treatment of acute gastric hemorrhage.

METHODS

The PUBMED, Web of Science, Wiley Library, EMBASE, Wanfang, CNKI, and VIP databases were searched for studies related to gastroscopic hemostatic treatment for acute GC published through February 20, 2023. The literature was screened according to the inclusion and exclusion criteria, data were extracted, and literature quality was evaluated. The meta-analysis was performed using RevMan software (version 5.3), while Begg's test for publication bias was performed using Stata 13.0 software.

RESULTS

Six randomized controlled trials and two retrospective analyses were retrieved.



Five studies had a low, two had an uncertain, and one had a high risk of bias. Compared with the control group, the hemostatic rate of gastroscopic hemostasis was increased [relative risk (RR) = 1.24; 95% confidence interval (CI): 1.08 to 1.43; P = 0.003]; the rate of rebleeding (RR = 0.27; 95% CI: 0.09 to 0.80; P = 0.02), rate of surgery transfer (RR = 0.16; 95% CI: 0.06 to 0.43; P = 0.0003), serum C-reactive protein level [mean difference (MD) = -5.16; 95% CI: -6.11 to 4.21; P < 0.00001], interleukin-6 level (MD = -6.37; 95%CI: -10.33 to -2.42; P = 0.002), and tumor necrosis factor- α level (MD = -2.29; 95% CI: -4.06 to -0.52; P = 0.01) were decreased; and the quality of life improvement rate was increased (RR = 1.95; 95% C I= 1.41-2.71; P < 0.0001). Begg's test revealed no significant publication bias.

CONCLUSION

The efficacy and safety of endoscopic hemostasis were higher than those of the control group, suggesting that it is an effective treatment for acute GC hemorrhage.

Key Words: Gastroscope; Gastric cancer; Acute bleeding; Curative effect; Security; Meta-analysis

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This meta-analysis provides a wealth of evidence emphasizing the effectiveness and safety of endoscopic hemostasis for treating acute gastrointestinal bleeding in patients with gastric cancer (GC). Compared with the control group, endoscopic hemostasis effectively controlled acute gastric bleeding in GC while significantly reducing the bleeding and transfer rates, indicating its efficacy at treating patients with acute gastric bleeding in GC. Nevertheless, further high-quality clinical research is required to confirm the safety and efficacy of endoscopic hemostasis in the treatment of acute GC bleeding.

Citation: Pan HY, Wang XW, He QX, Lu YD, Zhang WY, Jin JW, Lin B. Efficacy and safety of gastroscopic hemostasis in the treatment of acute gastric hemorrhage: A meta-analysis. World J Gastrointest Oncol 2023; 15(11): 1988-1997 URL: https://www.wjgnet.com/1948-5204/full/v15/i11/1988.htm DOI: https://dx.doi.org/10.4251/wjgo.v15.i11.1988

INTRODUCTION

Gastric cancer (GC) is a malignant tumor with one of the highest prevalence and mortality rates among all cancers worldwide. Acute hemorrhage from GC is a serious life-threatening complication [1-3]. GC-related bleeding accounts for an estimated 1%-8% of acute upper gastrointestinal bleeding cases [4,5]. Effective hemostatic treatment is crucial for patients with acute hemorrhage due to GC, as it can reduce the risk of mortality. Emergency gastroscopy can be used for rapid intervention, bleeding assessment, the identification of bleeding sources, and hemostatic treatment[6,7]. Thus, gastroscopic hemostasis is the preferred treatment for acute GC bleeding[8], although little evidence supports the use of endoscopic hemostatic treatment for acute GC bleeding.

The 30 d mortality rate of gastrointestinal bleeding in advanced GC after endoscopic hemostatic treatment is approximately 15.9%-43% higher than that of other causes of gastrointestinal bleeding[9-11]. However, some studies have shown that emergency gastroscopy can improve the detection rate of bleeding causes and aid the assessment of the risk of rebleeding and hemostatic effects[12,13]. The efficacy and safety of endoscopic hemostasis for the treatment of acute bleeding from GC remain controversial. Siau et al[14] reported that early gastroscopy could increase the risk of rebleeding. However, a recent study that included a large number of patients with GC (n = 45) reported a fairly low success rate for endoscopic hemostasis (31%). In the remaining 69% of GC bleeding cases, transarterial embolization was used to save patients after gastroscopy failed [15]. Therefore, this study aimed to systematically evaluate the efficacy and safety of gastroscopic hemostasis in the treatment of acute GC hemorrhage using a meta-analysis to objectively and accurately investigate this question.

MATERIALS AND METHODS

Search strategy

The PUBMED, Web of Science, Wiley Library, EMBASE, Wanfang, China National Knowledge Network, and VIP databases were searched for studies published from the inception of each database through February 20, 2023. The reference lists of all retrieved articles were manually searched to identify any other relevant studies.

The search used a combination of subjects and free words. The following English keywords and their Chinese counterparts were used in the search: Gastroscopy, emergency gastroscopy, hemostasis, gastric cancer, GC, acute bleeding, bleeding, and curative effects.



Literature inclusion criteria

The study inclusion criteria were as follows: (1) Randomized controlled study or retrospective analysis of gastroscopic hemostasis for the treatment of acute GC bleeding; (2) subjects including GC patients with acute gastric bleeding; (3) patients in the experimental group were treated with gastroscopy hemostasis, while patients in the control group were treated with conventional drugs; and (4) outcome indexes were successful hemostasis, rebleeding rate, transfer rate, serum C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor- α (TNF- α), and quality of life improvement, including at least one outcome measure.

Literature exclusion criteria

The study exclusion criteria were as follows: (1) Study subjects included individuals with GC accompanied by acute hemorrhage; (2) experimental group underwent endoscopic hemostasis treatment for managing bleeding, while the control group received conventional medication for hemostasis; (3) publication language not Chinese or English; (4) incomplete or missing data; and (5) duplicate publication.

Literature screening and data extraction

The literature was searched according to the specified search strategy and screened using the preferred reporting items for systematic reviews and meta-analyses flow chart. The literature was screened separately by two researchers and then crosschecked. In cases of disagreement, a third researcher was invited to participate in the discussions. Two researchers independently extracted the data in accordance with the designated data extraction table, including authors, publication date, country, sample size of the experimental and control groups, patient age, intervention measures, and original outcome data. After the study extraction process, both researchers performed cross-checking and a third researcher ruled out dispute cases.

Literature quality evaluation

This randomized controlled study evaluated the quality of the bias risk assessment tools recommended by the Cochrane Handbook and made judgments on the random allocation method, allocation hiding, blinding method, data integrity, selective reporting, and six other items. If all six items were answered "yes," the study was classified as having a low risk of bias; if all six items were answered "no" or "unclear," the study was classified as having an uncertain risk of bias; if all items were "no" or "unclear," the study was classified as having a high risk of bias. The Newcastle-Ottawa Scale (NOS) was used for the retrospective analysis. An NOS score < 5 was classified as a high risk of bias, while a score \geq 5 was classified as a low risk of bias.

Statistical methods

RevMan 5.4 software was used to process the data for the meta-analysis. Risk ratios (RR) and 95% confidence intervals (CI) were used to count the data, and the mean difference (MD) and 95%CI were used for measurement data. The Q test was used for the heterogeneity analysis. Values of P < 0.1 and $l^2 > 50\%$ indicated interstudy heterogeneity. The randomeffects model was used for the meta-analysis in these cases; otherwise, the fixed-effects model was used. Stata 13.0 software was used to perform Begg's test for the publication bias analysis. Statistical significance was set at P < 0.05.

RESULTS

Literature screening results

A total of 1998 papers were preliminarily retrieved from the databases; of them, 253 duplicates were removed using Endnote and NoteExpress, and 1745 papers remained. The title and abstract screening removed 1429 unqualified papers, leaving 316 papers. The full-text review eliminated 273 papers, leaving six randomized controlled trials (RCTs) and two retrospective studies[12,16-22] (Figure 1).

Basic information and guality evaluation of the included literature

Six RCTs and two retrospective studies were included in this study, including 672 patients (328 in the experimental group, 344 in the control group). General information about the included studies is presented in Table 1. The risk of bias in the included studies was evaluated using the Cochrane Handbook and NOS scale. Five studies had a low risk of bias, two had an uncertain risk of bias, and only one had a high risk of bias (Table 1).

Statistical analysis results

Analysis of hemostasis rate after gastroscopic hemostasis: Analyses of the hemostatic rates of gastroscopic hemostatic treatment were reported in seven studies (267 and 215 patients in the experimental and control groups, respectively). Due to moderate heterogeneity among the included studies (P = 0.0008, $l^2 = 74\%$), a random-effects analytical model was adopted. The meta-analysis results showed that the hemostasis rate of the experimental group was significantly higher than that of the control group (RR = 1.24; 95% CI: 1.08 to 1.43; P = 0.003) (Figure 2). Begg's test found no publication bias among the included studies (P > 0.05).

Analysis of rebleeding rate after gastroscopic hemostasis: Five studies reported analyses of rebleeding rates for gastroscopic hemostatic treatment (207 and 221 patients in the experimental and control groups, respectively). Due to moderate



Table 1	General inf	formation	of the inclu	uded studies

	Year of			Experimental group				Control group				Study	Risk of	
Ref.	publication	Country	Study type	Sample size	Age (yr)	Male/female Intervention methods Sample size	Age (yr)	Male/female	Intervention methods	- Study dates	bias	Outcomes		
Sheibani <i>et</i> al[<mark>16</mark>]	2013	United States	Retrospective analysis	14	57 ± 12	/	Gastroscopy hemostasis	18	57 ± 12	/	Drug hemostasis	2005.1- 2012.1	Low	1, 2, 3
Zheng[<mark>17</mark>]	2017	China	Retrospective analysis	30	55.1 ± 9.8	19/11	Emergency gastroscopy hemostasis	47	56.2 ± 11.0	31/16	Drug hemostasis	2011.3- 2016.1	High	1, 2, 3, 7
Zhang[<mark>18</mark>]	2018	China	RCT	32	55.47 ± 12.31	18/14	Emergency gastroscopy hemostasis	32	56.17 ± 11.62	19/13	Drug hemostasis	2015.1- 2017.3	Low	1, 2, 3, 4, 5, 6, 7
Long[<mark>19</mark>]	2019	China	RCT	36	58.95 ± 5.21	20/16	Emergency gastroscopy hemostasis	36	58.75 ± 5.62	21/15	Drug hemostasis	/	Unclear	1, 2
Qi et al <mark>[20</mark>]	2019	China	RCT	40	56.45 ± 3.23	/	Emergency gastroscopy hemostasis	40	56.45 ± 3.23	/	Drug hemostasis	2017.12- 2018.12	Low	1
Ren et al[12]	2021	China	RCT	93	49 ± 3.01	54/38	Emergency gastroscopy hemostasis	88	47 ± 3.83	47/41	Drug hemostasis	2018.9- 2020.9	Low	1, 2
Xiang[21]	2021	China	RCT	34	54.45 ± 2.15	19/15	Gastroscopy hemostasis	34	54.63 ± 2.26	18/16	Drug hemostasis	2019.8- 2020.12	Unclear	1, 5, 6
Zhang et al [<mark>22</mark>]	2021	China	RCT	49	56.6 ± 4.76	31/18	Gastroscopy hemostasis	49	56.55 ± 4.71	29/20	Drug hemostasis	2018.10- 2019.10	Low	3, 4, 5, 6, 7

1: Hemostasis success rate; 2: Rebleeding rate; 3: Operational transfer rate; 4: Patient's serum C-reactive protein level; 5: Serum interleukin-6 level; 6: Serum tumor necrosis factor-α level; 7: Quality of life improvement rate. RCT: Randomized controlled trial.

heterogeneity among the included studies (P = 0.004, $I^2 = 74\%$), a random-effects model of analysis was adopted. The meta-analysis results showed that the rebleeding rate in the experimental group was significantly lower than that in the control group (RR = 0.27; 95% CI: 0.09 to 0.80; P = 0.02) (Figure 3). Begg's test found no publication bias among the included studies (P > 0.05).

Transfer rate of hemostatic treatment under gastroscopy: Four studies analyzed the transfer rate for gastroscopic hemostatic treatment. A total of 125 and 146 patients were included in the experimental and control groups, respectively. There was no heterogeneity among the included studies (P = 0.19, $I^2 = 37\%$); therefore, a fixed-effects analytical model was adopted. The conversion rate of treatment was significantly lower in the experimental than control groups (RR = 0.16; 95% CI: 0.06 to 0.43; P = 0.0003) (Figure 4). Begg's test found no publication bias among the included studies (P > 0.05).

Analysis of serum CRP after gastroscopic hemostasis: Two studies reported analyses of serum CRP levels after gastroscopic hemostatic treatment (81 and 81 patients in the experimental and control groups, respectively). There was no




Figure 1 Literature screening flow chart and results.

Study or subgroup	Experin Events	nental Total	Contr Events		Weight	Risk ratio M-H. Random. 95%	Risk ratio Cl M-H. Random. 95%CI
Long 2019	35	36	30	36	15.8%	1.17 [1.00, 1.36]	
Qi 2019	38	40	33	40	15.6%	1.15 [0.98, 1.35]	
Ren 2021	89	93	52	88	14.8%	1.62 [1.35, 1.94]	
Sheibani 2013	12	14	18	18	12.5%	0.86 [0.67, 1.09]	
Xiang 2021	33	34	26	34	14.2%	1.27 [1.04, 1.54]	
Zhang 2018	31	32	23	32	13.0%	1.35 [1.08, 1.69]	· · · · · · · · · · · · · · · · · · ·
Zheng 2017	29	30	33	47	14.1%	1.38 [1.13, 1.68]	
Total (95% CI)		279		295	100.0%	1.24 [1.08, 1.43]	-
Total events	267		215				
Heterogeneity: Tau ² = 0	.03; Chi ² =	23.02. d	f = 6 (P =	= 0.000	(8); $I^2 = 74$	%	
Test for overall effect: Z					<i>,,</i>		0.5 0.7 1 1.5 2 Favours [experimental] Favours [control]
						DOI : 10.425	51/wjgo.v15.i11.1988 Copyright ©The Author(s) 2023.

Figure 2 Forest map comparing hemostatic rates of experimental and control groups after hemostatic treatment. Cl: Confidence interval.

heterogeneity among the included studies (P = 0.68, $I^2 = 0\%$); therefore, a fixed-effects analytical model was used. The meta-analysis results showed that mean serum CRP level was significantly lower in the experimental versus control group (MD = -5.16; 95%CI: -6.11 to -4.21; P < 0.00001) (Figure 5). Begg's test found no publication bias among the included studies (P > 0.05).

Analysis of serum IL-6 level for hemostatic treatment under gastroscopy: Three studies analyzed serum IL-6 levels after gastroscopic hemostatic treatment (115 and 115 patients in the experimental and control groups, respectively). Heterogeneity was detected among the included studies (P < 0.00001, $I^2 = 94\%$); therefore, a random-effects model of analysis was adopted. The meta-analysis results showed that the mean serum IL-6 level after treatment was significantly lower in the experimental versus control group (MD = -6.37; 95%CI: -10.33 to -2.42; P = 0.002) (Figure 6). Begg's test found no publication bias among the included studies (P > 0.05).

Analysis of serum TNF-a after gastroscopic hemostasis: An analysis of serum TNF-a after gastroscopic hemostasis was reported in three studies (115 and 115 patients in the experimental and control groups, respectively). Heterogeneity existed among the included studies (P < 0.0001, $I^2 = 98\%$); therefore, a random-effects analytical model was adopted. The



Roishidena® WJGO https://www.wjgnet.com




Figure 3 Forest map comparing rebleeding rates of experimental and control groups after hemostatic treatment. Cl: Confidence interval.

Study or subgroup	Experin Events		Contr Events		Weight	Risk ratio M-H. Fixed. 95%C	Risk ratio I M-H. Fixed. 95%Cl
Sheibani 2013	1	14	0	18	1.6%	3.80 [0.17, 86.76]	
Zhang 2018	1	32	8	32	28.3%	0.13 [0.02, 0.94]	
Zhang 2021	0	49	10	49	37.1%	0.05 [0.00, 0.79]	<
Zheng 2017	1	30	12	47	33.1%	0.13 [0.02, 0.95]	
Total (95% CI)		125		146	100.0%	0.16 [0.06, 0.43]	
Total events	3		30				
Heterogeneity: Chi ² = 4	.77, df = 3	(P = 0.1)	9); $I^2 = 37$	7%			
Test for overall effect: 2	Z = 3.62 (P	= 0.000	3)				0.01 0.1 1 10 100 Favours [experimental] Favours [control]
						DOI : 10.4	4251/wjgo.v15.i11.1988 Copyright ©The Author(s) 2023

Figure 4 Forest map comparing conversion rates of experimental and control groups after hemostatic treatment.Cl: Confidence interval.

Study or subgroup	Exper Mean				ontro SD		Weight	Mean difference IV. Fixed. 95%C			Mean dif IV. Fixed			
Zhang 2018	7.78	2.95	32	12.65	3.84	32	32.0%	-4.87 [-6.55, -3.19]		-	_			
Zhang 2021	7.2	1.8	49	12.5	3.7	49	68.0%	-5.30 [-6.45, -4.15]			-			
Total (95% CI)			81			81	100.0%	-5.16 [-6.11, -4.21]		•				
Heterogeneity: Chi ² =		,	,		þ				⊢ -10	-5))	5	10
Test for overall effect:	Z = 10.6	5 (P <	0.0000	1)						Favours [ex	perimental]	Favours [c	ontrol]	10
								DOI : 10.42	51/w	jgo.v15.i11.	1988 Copy	right ©The	e Author	(s) 2023.

Figure 5 Forest map comparing serum C-reactive protein levels of experimental and control groups after hemostatic treatment. Cl: Confidence interval.

Study or subgroup	Exper Mean				ontro SD		Weight	Mean difference IV. Random. 95%			difference ndom. 95%		
Xiang 2021	9.1	1.58	34	12.3	1.1	34	35.9%	-3.20 [-3.85, -2.55]		1			
Zhang 2018	7.56	3.84	32	15.66	7.45	32	30.4%	-8.10 [-11.00, -5.20]					
Zhang 2021	7.6	2	49	15.8	6.2	49	33.7%	-8.20 [-10.02, -6.38]					
Total (95% CI)			115			115	100.0%	-6.37 [-10.33, -2.42]			-		
Heterogeneity: Tau ² =	11.23; C	Chi² = 3	3.86, d	f = 2 (P	< 0.00	001); <i>I</i>	² = 94%		L	10		10	
Test for overall effect:	Z = 3.16	(<i>P</i> = 0	.002)						-20 Favo	-10 ours [experimer	ntal] Favour	10 s [control]	20
								DOT: 10 4251	/wice vi	E 11 1000 Co		Author(c)	2022

DOI: 10.4251/wjgo.v15.i11.1988 **Copyright** ©The Author(s) 2023.

Figure 6 Forest map comparing serum interleukin-6 Levels of experimental and control groups after hemostatic treatment. CI: Confidence interval.

mean serum TNF- α level after treatment was significantly lower in the experimental vs control group (MD = -2.29; 95% CI: -4.06 to 0.52; P = 0.01) (Figure 7). Begg's test found no publication bias in the included studies (P > 0.05).

Improvement of quality of life after gastroscopic hemostasis: Three studies analyzed the quality of life improvement rate after gastroscopic hemostasis (111 and 128 patients in the experimental and control groups, respectively). No heterogeneity was noted among the included studies (P = 0.97, $I^2 = 0\%$); therefore, a fixed-effects analytical model was adopted.

Pan HY et al. Gastroscopic hemostasis in acute gastric hemorrhage




Figure 7 Forest map comparing serum tumor necrosis factor-α levels of experimental and control groups after hemostatic treatment. CI: Confidence interval.

The quality of life improvement rate after treatment was higher in the experimental versus control group (RR = 1.95; 95% CI: 1.41 to 2.71; P < 0.0001) (Figure 8). Begg's test found no publication bias among the included studies (P > 0.05).

DISCUSSION

Acute hemorrhage in GC is a common form of gastrointestinal hemorrhage. In response to the high recurrence and malignancy rates of GC[1,6,23-25], great progress has been made in recent years toward improving the diagnostic process and multidisciplinary treatment strategy for resectable GC. However, owing to the high recurrence rate, the patient survival rate is still not ideal[26-28]. Gastroscopic hemostatic treatment can effectively prevent acute bleeding and reduce patient fatality rates, thus aiding the treatment of these patients[12,16]. However, published literature related to the efficacy and safety of endoscopic hemostasis in the treatment of acute GC bleeding is controversial and shows strong differences[14,15]. Therefore, this meta-analysis aimed to evaluate the efficacy and safety of endoscopic hemostasis for the treatment of acute GC-related bleeding by summarizing various studies.

Our results showed that gastroscopic hemostasis could effectively control acute bleeding in GC and that the hemostasis rate was much higher in the treatment vs control group. In addition, the rebleeding and surgical transfer rates were significantly reduced. Thus, endoscopic hemostasis for the treatment of acute bleeding in patients with GC has a relatively high success rate, consistent with previous findings[12,16,29]. In the context of acute bleeding in GC, this metaanalysis particularly emphasizes the elevation of CRP, IL-6, and TNF- α levels[9,12,16,20]. These inflammatory factors play multiple roles in the development of GC. They can promote the proliferation and survival of cancer cells by activating specific signaling pathways such as phosphoinositide 3-kinase/protein kinase B and mitogen-activated protein kinase[30, 31]. Moreover, high levels of inflammatory factors promote angiogenesis by providing abundant nutrients to cancer cells [32]. Additionally, the inflammatory microenvironment may locally alter the composition and stiffness of the extracellular matrix locally, thereby facilitating cancer cell invasion and migration[33].

Several studies demonstrated that inflammatory factors play an important role in GC patients with acute bleeding. Serum levels of CRP, IL-6, and TNF- α gradually increase in patients with acute bleeding in GC[18,22,34]. Therefore, when bleeding is controlled, the levels of CRP, IL-6, and TNF- α tend to decrease. Consistent with these findings, our study reached the same conclusion: Serum levels of CRP, IL-6, and TNF- α were significantly lower in the experimental vs control group, indicating that endoscopic hemostasis treatment had better hemostatic control than the control treatment. Moreover, the quality of life of the patients in the endoscopic treatment group improved significantly.

The GC microenvironment is a highly complex biological system that includes tumor cells, immune cells, fibroblasts, various cytokines, and chemical factors[19]. In this environment, immune cells such as tumor-associated macrophages and T cells may further influence the tumor growth dynamics and the risk of bleeding in patients by releasing pro- and anti-inflammatory factors[35]. Some studies found a correlation between high levels of transforming growth factor- β and low levels of interferon- γ with an increased risk of bleeding[9,12]. Although endoscopic hemostasis is widely used to control acute bleeding in GC, the specific molecular mechanisms are not fully understood. In contrast, endoscopic treatment may achieve hemostasis by activating the coagulation cascade, promoting platelet aggregation, and regulating certain inflammatory and coagulation factors[36]. Evidence suggests that these treatment modalities may reduce local inflammatory and immune responses have been observed in other gastrointestinal cancers such as esophageal and colorectal cancer[37,38]. These observations not only provide valuable perspectives for comparing different types of gastrointestinal cancers, but they also have the potential to reveal common therapeutic strategies for this class of cancer.

The limitations of this study are as follows: (1) Because meta-analyses summarize only published studies, they were limited by the quality of the original studies, and the overall quality of the studies included here was low; (2) this meta-analysis included only published studies, while unpublished studies were not considered; and (3) the number of studies and sample size included here were small. These factors may have affected the accuracy and reliability of the results.

Zaisbideng® WJGO | https://www.wjgnet.com

Study or subgroup	Experimenta Events Tota	l Control I Events Total	Weight	Risk ratio M-H. Fixed. 95%Cl	Risk ratio M-H. Fixed. 95%Cl
Zhang 2018	18 32	9 32	27.2%	2.00 [1.06, 3.76]	
Zhang 2021	26 49	14 49	42.3%	1.86 [1.11, 3.11]	— — —
Zheng 2017	17 30	13 47	30.6%	2.05 [1.17, 3.58]	
Total (95% Cl)	111	128	100.0%	1.95 [1.41, 2.71]	
Total events	61	36			
Heterogeneity: Chi ² = 0	.07, df = 2 (P = 0	.97); <i>I</i> ² = 0%		H	
Test for overall effect: Z	$L = 4.04 \ (P < 0.00)$	001)		0	0.1 0.2 0.5 1 2 5 10 Favours [experimental] Favours [control]
				DOI : 10.425	1/wjgo.v15.i11.1988 Copyright ©The Author(s) 2023.

Figure 8 Forest map comparing quality of life improvement rates of experimental and control groups after hemostatic treatment. Cl: Confidence interval.

CONCLUSION

In conclusion, RCTs with larger sample sizes and better quality standards should be conducted to further clarify the safety and effectiveness of gastroscopic hemostasis for the treatment of acute GC bleeding.

ARTICLE HIGHLIGHTS

Research background

Gastric cancer (GC) is a malignant tumor with a high incidence and mortality rate worldwide for which acute bleeding is a common clinical complication.

Research motivation

Gastroscopic hemostasis is an important method for treating acute bleeding in GC; however, its efficacy and safety remain controversial.

Research objectives

This meta-analysis provides a wealth of evidence emphasizing the effectiveness and safety of endoscopic hemostasis for treating acute gastrointestinal bleeding in patients with GC.

Research methods

Several databases was searched for related to gastroscopic hemostatic treatment for acute GC. The literature was screened according to the inclusion and exclusion criteria, data were extracted, and literature quality was evaluated. The metaanalysis was performed using RevMan software (version 5.3), while Begg's test for publication bias was performed using Stata 13.0 software.

Research results

Compared with the control group, the hemostatic rate of gastroscopic hemostasis was increased [relative risk (RR) = 1.24; 95% confidence interval (CI) = 1.08-1.43; P = 0.003]; the rate of rebleeding (RR = 0.27; 95% CI: 0.09 to 0.80; P = 0.02), rate of surgery transfer (RR = 0.16; 95% CI: 0.06 to 0.43; P = 0.0003), serum C-reactive protein level [mean difference (MD) = -5.16; 95% CI: -6.11 to 4.21; *P* < 0.00001], interleukin-6 level (MD = -6.37; 95% CI: -10.33 to -2.42; *P* = 0.002), and tumor necrosis factor- α level (MD=-2.29; 95% CI: -4.06 to -0.52; P = 0.01) were decreased; and the quality of life improvement rate was increased (RR = 1.95; 95%CI: 1.41 to 2.71; *P* < 0.0001).

Research conclusions

The efficacy and safety of endoscopic hemostasis were higher than those of the control group.

Research perspectives

Endoscopic hemostasis is an effective treatment for acute GC hemorrhage.

ACKNOWLEDGEMENTS

The authors are grateful to the participating researchers for their contributions. We thank the reviewers and editors for their valuable suggestions.



FOOTNOTES

Author contributions: Lin B and Pan HY contributed to conception and design; Lin B contributed to administrative support; Lin B and Pan HY contributed to provision of study materials or patients; Pan HY, Wang XW, He QX, Lu YD; Zhang WY, Jin JW and Lin B contributed to collection and assembly of data; Lin B and Pan HY contributed to data analysis and interpretation; All authors contributed to manuscript writing, final approval of manuscript.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Bin Lin 0009-0008-4327-1114.

S-Editor: Ou XL L-Editor: A P-Editor: Zhang XD

REFERENCES

- Zhou XQ, Chang YZ, Shen CY, Han J, Chang RA. Xiaoaiping injection combined with chemotherapy for advanced gastric cancer: An updated 1 systematic review and meta-analysis. Front Pharmacol 2022; 13: 1023314 [PMID: 36249747 DOI: 10.3389/fphar.2022.1023314]
- Yang S, Zou X, Li J, Yang H, Zhang A, Zhu Y, Zhu L, Zhang L. Immunoregulation and clinical significance of neutrophils/NETs-ANGPT2 in 2 tumor microenvironment of gastric cancer. Front Immunol 2022; 13: 1010434 [PMID: 36172371 DOI: 10.3389/fimmu.2022.1010434]
- Zhang X, Tsauo J, Tie J, Xue H, Zhao JB, Li JJ, Fang ZT, Guo WH, Li X. Emergent Transjugular Intrahepatic Portosystemic Shunt Creation 3 for Acute Gastric Variceal Bleeding in Patients with Hepatocellular Carcinoma. J Vasc Interv Radiol 2022; 33: 702-706 [PMID: 35636835 DOI: 10.1016/j.jvir.2022.03.012]
- 4 Reitano E, de'Angelis N, Bianchi G, Laera L, Spiliopoulos S, Calbi R, Memeo R, Inchingolo R. Current trends and perspectives in interventional radiology for gastrointestinal cancers. World J Radiol 2021; 13: 314-326 [PMID: 34786187 DOI: 10.4329/wjr.v13.i10.314]
- Ortega Rodriguez AA, Cohn Reinoso CM, Mateu Esquerda G, de Manuel-Rimbau Muñoz J. Spontaneous acute bleeding within subdural 5 effusion from dural metastasis of gastric cancer: A case report. Neurocirugia (Astur : Engl Ed) 2022; 33: 340-344 [PMID: 36333090 DOI: 10.1016/i.neucie.2021.04.009
- Zhao YX, Yang Z, Ma LB, Dang JY, Wang HY. Synchronous gastric cancer complicated with chronic myeloid leukemia (multiple primary 6 cancers): A case report. World J Clin Cases 2022; 10: 11146-11154 [PMID: 36338220 DOI: 10.12998/wjcc.v10.i30.11146]
- 7 Dai L, Jiang C, Hong D, He X, Zeng X, Li H, Li S, Li D, Wang W. A prospective, open-labeled, and randomized trial for assessing safety and clinical utility of gastric biopsies during emergency gastroscopy for patients with bleeding gastric ulcers. Scand J Gastroenterol 2023; 58: 549-557 [PMID: 36384392 DOI: 10.1080/00365521.2022.2147275]
- Khorobrykh TV, Abdulkhakimov NM, Agadzhanov VG, Aghayan DL, Kazaryan AM. Laparoscopic versus open surgery for locally advanced 8 and metastatic gastric cancer complicated with bleeding and/or stenosis: short- and long-term outcomes. World J Surg Oncol 2022; 20: 216 [PMID: 35752852 DOI: 10.1186/s12957-022-02674-3]
- Song IJ, Kim HJ, Lee JA, Park JC, Shin SK, Lee SK, Lee YC, Chung H. Clinical Outcomes of Endoscopic Hemostasis for Bleeding in Patients 9 with Unresectable Advanced Gastric Cancer. J Gastric Cancer 2017; 17: 374-383 [PMID: 29302377 DOI: 10.5230/jgc.2017.17.e42]
- Kim YI, Choi IJ, Cho SJ, Lee JY, Kim CG, Kim MJ, Ryu KW, Kim YW, Park YI. Outcome of endoscopic therapy for cancer bleeding in patients with unresectable gastric cancer. J Gastroenterol Hepatol 2013; 28: 1489-1495 [PMID: 23662891 DOI: 10.1111/jgh.12262]
- Kim YI, Choi IJ. Endoscopic management of tumor bleeding from inoperable gastric cancer. Clin Endosc 2015; 48: 121-127 [PMID: 11 25844339 DOI: 10.5946/ce.2015.48.2.121]
- Ren T, Wei J, Han B, Chen X, Zhong J, Lan F. The clinical effect of emergency gastroscopy on upper gastrointestinal hemorrhage patients. Am 12 J Transl Res 2021; 13: 3501-3507 [PMID: 34017528 DOI: 10.47939/mh.v2i8.254]
- Takeda K, Sakayauchi T, Kubozono M, Katagiri Y, Umezawa R, Yamamoto T, Ishikawa Y, Takahashi N, Suzuki Y, Kishida K, Jingu K. 13 Palliative radiotherapy for gastric cancer bleeding: a multi-institutional retrospective study. BMC Palliat Care 2022; 21: 52 [PMID: 35413824 DOI: 10.1186/s12904-022-00943-2]
- Siau K, Chapman W, Sharma N, Tripathi D, Iqbal T, Bhala N. Management of acute upper gastrointestinal bleeding: an update for the general 14 physician. J R Coll Physicians Edinb 2017; 47: 218-230 [PMID: 29465096 DOI: 10.4997/JRCPE.2017.303]
- Koh KH, Kim K, Kwon DH, Chung BS, Sohn JY, Ahn DS, Jeon BJ, Kim SH, Kim IH, Kim SW, Lee SO, Lee ST, Kim DG. The successful 15 endoscopic hemostasis factors in bleeding from advanced gastric cancer. Gastric Cancer 2013; 16: 397-403 [PMID: 23053826 DOI: 10.1007/s10120-012-0200-3]
- Sheibani S, Kim JJ, Chen B, Park S, Saberi B, Keyashian K, Buxbaum J, Laine L. Natural history of acute upper GI bleeding due to tumours: 16 short-term success and long-term recurrence with or without endoscopic therapy. Aliment Pharmacol Ther 2013; 38: 144-150 [PMID: 23710797 DOI: 10.1111/apt.12347]



- Zheng C. Clinical efficacy and safety of emergency gastroscopy in the treatment of acute hemorrhage in patients with gastric cancer. Shiyong 17 Aizheng Zazhi 2017; 32: 638-640 [DOI: 10.3969/j.issn.1001-5930.2017.04.034]
- Zhang JK. Curative effect of emergency gastroscopy on upper gastrointestinal acute hemorrhage caused by gastric cancer. Xiandai Shiyong 18 *Yixue* 2018; **30**: 1164-1166 [DOI: 10.3969/j.issn.1671-0800.2018.09.022]
- Long P. Clinical effect and safety of emergency gastroscopy in the treatment of acute hemorrhage of gastric cancer. Zhonghua Zhongliu 19 Fangzhi Zazhi 2019; 26: 71
- Qi L, Wang C, Wang J. Clinical Effect of Emergency Gastroscopy on Acute Bleeding of Gastric Cancer. Proceedings of Anticancer Research 20 2019; 3: 9-12
- Xiang LQ. Effect analysis of gastroscopic hemostasis in the treatment of advanced gastric cancer with acute bleeding. Dangdai Yiyao Luncong 21 2021; 19: 33-35 [DOI: 10.3969/j.issn.2095-7629.2021.15.017]
- Zhang H, Peng B, Zhang CQ, Li ZY, Long C. Clinical efficacy and safety evaluation of emergency gastroscopy in the treatment of acute 22 hemorrhage of gastric cancer. Xiandai Xiaohua Ji Jieru Zhenliao 2021; 26: 463-466
- 23 Lee J, Byun HK, Koom WS, Lee YC, Seong J. Efficacy of radiotherapy for gastric bleeding associated with advanced gastric cancer. Radiat Oncol 2021; 16: 161 [PMID: 34425855 DOI: 10.1186/s13014-021-01884-5]
- 24 Kamposioras K, Geraghty J, Appleyard J, Dawod M, Papadimitriou K, Lamarca A, Anthoney A. Pancreaticobiliary Malignancies in the Emergency Room: Management of Acute Complications and Oncological Emergencies. J Gastrointest Cancer 2022; 53: 1050-1065 [PMID: 34648136 DOI: 10.1007/s12029-021-00718-7]
- Orii T, Karasawa Y, Kitahara H, Yoshimura M, Okumura M. Efficacy of Self-Expandable Metallic Stent Inserted for Refractory Hemorrhage 25 of Duodenal Cancer. Case Rep Gastroenterol 2016; 10: 151-156 [PMID: 27403118 DOI: 10.1159/000445738]
- 26 Huang H, Xu F, Chen Q, Hu H, Qi F, Zhao J. The value of CT-based radiomics nomogram in differential diagnosis of different histological types of gastric cancer. Phys Eng Sci Med 2022; 45: 1063-1071 [PMID: 36063347 DOI: 10.1007/s13246-022-01170-y]
- Taboada AGM, Lominchar PL, Roman LM, García-Alfonso P, Martin AJM, Rodriguez JAB, Pascual JMA. Advances in neoadjuvant therapy 27 for resectable pancreatic cancer over the past two decades. Ann Hepatobiliary Pancreat Surg 2021; 25: 179-191 [PMID: 34053920 DOI: 10.14701/ahbps.2021.25.2.179
- Zhu Z, Gong YB, Xu HM. Neoadjuvant therapy strategies for advanced gastric cancer: Current innovations and future challenges. Chronic Dis 28 Transl Med 2020; 6: 147-157 [PMID: 32908968 DOI: 10.1016/j.cdtm.2020.03.004]
- 29 Gao DJ, Wang SP, Fu XH, Yin L, Ye X, Yang XW, Zhang YJ, Hu B. Urgent Endoscopy Improves Hemostasis in Patients With Upper Gastrointestinal Bleeding Following Biliary-pancreatic Surgery: A Retrospective Analysis. Surg Laparosc Endosc Percutan Tech 2021; 32: 228-235 [PMID: 34966156 DOI: 10.1097/SLE.000000000001027]
- Patrad E, Khalighfard S, Amiriani T, Khori V, Alizadeh AM. Molecular mechanisms underlying the action of carcinogens in gastric cancer 30 with a glimpse into targeted therapy. Cell Oncol (Dordr) 2022; 45: 1073-1117 [PMID: 36149600 DOI: 10.1007/s13402-022-00715-3]
- 31 Gao XF, He HQ, Zhu XB, Xie SL, Cao Y. LncRNA SNHG20 promotes tumorigenesis and cancer stemness in glioblastoma via activating PI3K/Akt/mTOR signaling pathway. Neoplasma 2019; 66: 532-542 [PMID: 30943748 DOI: 10.4149/neo_2018_180829N656]
- Wang Y, Wu H, Deng R. Angiogenesis as a potential treatment strategy for rheumatoid arthritis. Eur J Pharmacol 2021; 910: 174500 [PMID: 32 34509462 DOI: 10.1016/j.ejphar.2021.174500]
- Magdeldin T, López-Dávila V, Pape J, Cameron GW, Emberton M, Loizidou M, Cheema U. Engineering a vascularised 3D in vitro model of 33 cancer progression. Sci Rep 2017; 7: 44045 [PMID: 28276469 DOI: 10.1038/srep44045]
- Navaei-Alipour N, Mastali M, Ferns GA, Saberi-Karimian M, Ghayour-Mobarhan M. The effects of honey on pro- and anti-inflammatory 34 cytokines: A narrative review. Phytother Res 2021; 35: 3690-3701 [PMID: 33751689 DOI: 10.1002/ptr.7066]
- Choo YW, Kang M, Kim HY, Han J, Kang S, Lee JR, Jeong GJ, Kwon SP, Song SY, Go S, Jung M, Hong J, Kim BS. M1 Macrophage-35 Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors. ACS Nano 2018; 12: 8977-8993 [PMID: 30133260 DOI: 10.1021/acsnano.8b02446]
- Sartim MA, Costa TR, Laure HJ, Espíndola MS, Frantz FG, Sorgi CA, Cintra AC, Arantes EC, Faccioli LH, Rosa JC, Sampaio SV. 36 Moojenactivase, a novel pro-coagulant PIIId metalloprotease isolated from Bothrops moojeni snake venom, activates coagulation factors II and X and induces tissue factor up-regulation in leukocytes. Arch Toxicol 2016; 90: 1261-1278 [PMID: 26026608 DOI: 10.1007/s00204-015-1533-6]
- 37 Men F, Wei L, Liu B, Wu F, Liu J, Guo N, Niu Q. Comparison of the safety of the application of painless gastroscopy and ordinary gastroscopy in chronic hypertension patients combined with early gastric cancer. Oncol Lett 2018; 15: 3558-3561 [PMID: 29467876 DOI: 10.3892/ol.2018.7737
- Xu F, Feng GS, Wang ZJ, Zhang KN. Synchronous double cancers of colonic large cell neuroendocrine carcinoma and gastric squamous-cell 38 carcinoma: a case report and review of literature. Int J Clin Exp Pathol 2014; 7: 5177-5180 [PMID: 25197393 DOI: 10.3389/pore.2023.1610902





Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: bpgoffice@wjgnet.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

